celiprolol has been researched along with Hypertension in 142 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celiprolol is a third-generation, beta-adrenoceptor antagonist with ancillary pharmacologic properties that are potentially advantageous in the treatment of hypertension." | 10.16 | Celiprolol in hypertension. ( Taylor, SH, 1988) |
| "It can be concluded that subjects with moderate hypercholesterolemia and hypertension benefit more from lipid-lowering treatment with simvastatin than from blood pressure-lowering with beta blocker celiprolol." | 9.12 | Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study). ( Kalliomäki, T; Makkonen, N; Olkinuora, JT; Vanhanen, H; Viikari, J, 2006) |
| "The present study was undertaken to clarify whether celiprolol and atenolol, beta1-selective beta blockers with and without intrinsic sympathomimetic activity (ISA), respectively, might improve ischemic damage in the isolated perfused hearts of spontaneously hypertensive rats (SHR), and whether long-term treatment with celiprolol may reduce left ventricular hypertrophy (LVH) in patients with essential hypertension." | 9.09 | Effect of celiprolol on cardiac hypertrophy in hypertension. ( Haneda, T; Honda, H; Kataoka, R; Kato, J; Kikuchi, K; Matsuhashi, H; Morimoto, H; Ogawa, Y; Takenaka, T; Tanazawa, S, 2000) |
| "The effects of celiprolol on insulin sensitivity, glucose tolerance and serum lipids were compared to those of other antihypertensive drugs (beta- or Ca-blocker or ACE-inhibitor) in 23 dyslipidemic non-diabetic patients with controlled hypertension." | 9.08 | Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension. ( Huupponen, R; Lahtela, JT; Malminiemi, K, 1995) |
| " Therefore, the changes of haemostasis parameters in 22 patients with essential hypertension under long-term celiprolol therapy (> 2 months) were of interest." | 9.08 | Effect of long-term celiprolol therapy on haemostasis in essential hypertension. ( Kratochvílová, H; Okrucká, A; Pechán, J, 1995) |
| "The hemodynamic effects of celiprolol (CAS 56980-93-9), a betablocker with beta 1 antagonist and beta 2 agonist properties, were compared with those of atenolol (CAS 29122-68-7) in 12 patients with mild to moderately severe hypertension (diastolic BP 95-110 mmHg)." | 9.08 | Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension. ( Mahler, F; Saner, H; Seiler, A, 1995) |
| "The effects of a vasodilating beta-blocker, celiprolol, on insulin sensitivity and cardiovascular risk factors were compared with those of another beta1-selective adrenoceptor blocker, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors." | 9.08 | Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents. ( Ala-Kaila, K; Huupponen, R; Lahtela, J; Malminiemi, K; Malminiemi, O, 1998) |
| " To test whether this criterion is fulfilled by celiprolol, a new beta 1-selective adrenergic blocker drug with peripheral vasodilating activity, we examined the effects of its oral administration on cardiovascular reactivity to laboratory stressors in 18 patients with essential hypertension, according to a placebo-controlled crossover design." | 9.07 | Effects of celiprolol on cardiovascular reactivity to laboratory stressors in patients with hypertension. ( Cardillo, C; De Felice, F; Degen, C; Folli, G, 1992) |
| "The immediate and short-term (2 week) hemodynamic and humoral effects of the beta-1 antagonist, beta-2 agonist, celiprolol, were compared with those of more prolonged atenolol therapy in 12 patients with essential hypertension." | 9.07 | Hemodynamic effects of celiprolol in essential hypertension. ( Frohlich, ED; Kaesser, UR; Ketelhut, R; Losem, CJ; Messerli, FH, 1991) |
| "A randomized double-blind study compared the antihypertensive efficacy of single daily oral doses of celiprolol 200 or 400 mg to twice daily doses of propranolol 40 or 80 mg in 58 patients with uncomplicated essential hypertension (supine diastolic blood pressure range 95-114 mm Hg)." | 9.06 | Celiprolol in the treatment of hypertension: a comparison with propranolol. ( Beattie, A; Silke, B; Taylor, SH, 1986) |
| " In two, randomized, placebo-controlled, 5-way crossover trials, the pulmonary effects of celiprolol 200 and 400 mg, propranolol 40 mg and atenolol 100 mg were compared in 34 asthmatic patients." | 9.06 | Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients. ( Applin, WJ; Brown, R; Caruso, FS; Doshan, HD; Rosenthal, RR; Slutsky, A, 1986) |
| "The antihypertensive effects of equivalent beta-blocking doses of atenolol and celiprolol were compared in 55 patients with mild to moderate hypertension." | 9.06 | A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension. ( Rosenthal, F; Silke, B; Taylor, S, 1986) |
| "The safety and efficacy of orally administered celiprolol, a new beta 1-selective adrenergic blocking drug with peripheral beta 2-agonist properties, were assessed in 91 patients with mild to moderate systemic hypertension (supine diastolic blood pressure [BP] 95 to 114 mm Hg without medication) using a placebo-controlled, double-blind, randomized, titration-to-effect study design." | 9.06 | Celiprolol in systemic hypertension. ( Flamenbaum, W; Frishman, WH; Godfrey, JC; Greenberg, S; Lazar, E; Neri, GS; Schoenberger, J; Schwartz, GL; Stevenson, A; Vidt, DG, 1989) |
| "Previous studies have shown that single dose or short-term administration of celiprolol does not impair pulmonary function in patients with asthma." | 9.06 | Effect of long-term treatment with celiprolol on pulmonary function in a group of mild hypertensive asthmatics. ( Clauzel, AM; Etienne, R; Jean, T; Michel, F; Visier, S, 1988) |
| "The effects of two cardioselective beta-adrenergic blocking agents--celiprolol (claimed to have bronchodilator properties) and atenolol (without such claims)--on respiratory function and control of asthma were studied in ten asthmatic patients with mild to moderate essential hypertension." | 9.06 | Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension. ( Bateman, ED; Jennings, AA; Opie, LH; van Zyl, AI, 1989) |
| "A two-centre, double-blind, placebo controlled, randomized 3-way crossover study was undertaken to assess the efficacy, tolerability and safety of celiprolol in mild to moderate essential hypertension." | 9.06 | A multi-centre, placebo controlled comparative study between 200 mg and 400 mg celiprolol in patients with mild to moderate essential hypertension. ( Ankier, SI; Latta, D; Little, PS; Parsley, J; Quail, D; Trafford, JA, 1989) |
| "The bronchopulmonary effects of celiprolol were studied in 12 male asthmatic patients who showed mean maximum changes of -24% in forced one-second expiratory volume (FEV1) and 130% in airways resistance (Raw) following a single, 80 mg dose of propranolol." | 9.06 | Bronchosparing properties of celiprolol, a new beta 1, alpha 2-blocker, in propranolol-sensitive asthmatic patients. ( Applin, WJ; Braig, H; Doshan, HD; Matthys, H; Pohl, M; Rühle, KH, 1986) |
| "The authors investigated in 18 patients with essential hypertension the action of celiprolol (usually in combination with a diuretic) on the glucose and lipid metabolism in an open three-month trial." | 7.70 | [Celiprolol improves glucose metabolism in essential hypertension]. ( Dzúrik, R; Fedelesová, V; Oksa, A; Spustová, V, 1998) |
| "In 30 hypertensives with angina pectoris the acute action of beta-blockers Celiprolol and Metoprolol on the global and coronary haemodynamics was tested within cardiac catheter diagnostics." | 7.68 | [Acute changes of coronary and global hemodynamics in patients with angina pectoris and arterial hypertension caused by celiprolol and metoprolol]. ( Bruch, L; Franz, N; Gola, G; Heublein, B; Linss, G; Modersohn, D; Walde, T, 1990) |
| "Arterial blood pressure and central hemodynamic changes were assessed in 44 patients with essential hypertension, uncontrollable by prazosin alone, after propranolol (anaprilin), celiprolol, clonidine (clofelin) or verapamil were added to the treatment schedule." | 7.67 | [Hemodynamic effect of a combination of prazosin with cardiac depressants in the treatment of hypertension]. ( Akopian, LM; Basem, AS; Ivleva, AIa; Krasnobaeva, GM; Moiseev, VS, 1988) |
| "Celiprolol is a 'third generation' beta-blocking agent which is claimed to avoid problems associated with simpler beta-blockers, such as vasoconstriction, bronchoconstriction and myocardial depression." | 6.67 | Acute haemodynamic profile of celiprolol in patients with coronary heart disease and hypertension: a double-blind comparison with metoprolol. ( Franz, N; Heublein, B; Modersohn, D; Panzner, B, 1991) |
| "Celiprolol is a newly developed cardioselective beta-blocking agent with mild beta 2-agonist and weak alpha 2-antagonist properties." | 6.66 | Effects of celiprolol on plasma renin, aldosterone, norepinephrine and epinephrine in primary hypertension. ( DeQuattro, V; Hernandez, PH; Kimura, S; Lee, DD, 1988) |
| "Celiprolol has shown equivalent antihypertensive efficacy to other beta-blockers, notably propranolol, atenolol, metoprolol and pindolol, in patients aged 18 to 75 years with mild to moderate essential hypertension." | 6.39 | Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. ( Dunn, CJ; Spencer, CM, 1995) |
| "Celiprolol hydrochloride is a cardioselective beta 1-adrenergic antagonist with partial agonist activity." | 6.38 | Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly. ( Lamon, KD, 1991) |
| "Celiprolol is a new 'cardioselective' beta-adrenoceptor blocking drug with intrinsic sympathomimetic (partial agonist) activity and a weak vasodilating effect." | 6.37 | Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. ( Brogden, RN; Riddell, JG; Shanks, RG, 1987) |
| "Celiprolol is a third-generation, beta-adrenoceptor antagonist with ancillary pharmacologic properties that are potentially advantageous in the treatment of hypertension." | 6.16 | Celiprolol in hypertension. ( Taylor, SH, 1988) |
| "Treatment with celiprolol was not associated with considerable heart rate decrease or changes of stroke volume and cardiac output." | 5.31 | [Use of selective long-acting beta-blocker with vasodilating activity celiprolol in patients with essential hypertension]. ( Mozharova, LG; Podzolkov, VI, 2002) |
| "Essential hypertension is associated with an increased incidence of insulin resistance of skeletal muscle glucose transport." | 5.30 | The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats. ( Dietze, GJ; Fogt, DL; Henriksen, EJ; Jacob, S, 1999) |
| "Celiprolol was administered orally in the daily dose of 300 mg." | 5.29 | [Celiprolol increases the microcirculation in subcutaneous tissue and calf muscles in essential hypertension]. ( Balazovjech, I; Cesnaková, Z; Pechán, J, 1993) |
| "It can be concluded that subjects with moderate hypercholesterolemia and hypertension benefit more from lipid-lowering treatment with simvastatin than from blood pressure-lowering with beta blocker celiprolol." | 5.12 | Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study). ( Kalliomäki, T; Makkonen, N; Olkinuora, JT; Vanhanen, H; Viikari, J, 2006) |
| "The angiotensinogen M235T polymorphism has been linked to hypertension and cardiovascular disease." | 5.10 | Angiotensinogen gene M235T polymorphism and reduction in wall thickness in response to antihypertensive treatment. ( Boutouyrie, P; Bozec, E; Dabire, H; Fassot, C; Jeunemaitre, X; Lacolley, P; Laurent, S; Tropeano, AI, 2003) |
| "The present study was undertaken to clarify whether celiprolol and atenolol, beta1-selective beta blockers with and without intrinsic sympathomimetic activity (ISA), respectively, might improve ischemic damage in the isolated perfused hearts of spontaneously hypertensive rats (SHR), and whether long-term treatment with celiprolol may reduce left ventricular hypertrophy (LVH) in patients with essential hypertension." | 5.09 | Effect of celiprolol on cardiac hypertrophy in hypertension. ( Haneda, T; Honda, H; Kataoka, R; Kato, J; Kikuchi, K; Matsuhashi, H; Morimoto, H; Ogawa, Y; Takenaka, T; Tanazawa, S, 2000) |
| "The effects of celiprolol on insulin sensitivity, glucose tolerance and serum lipids were compared to those of other antihypertensive drugs (beta- or Ca-blocker or ACE-inhibitor) in 23 dyslipidemic non-diabetic patients with controlled hypertension." | 5.08 | Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension. ( Huupponen, R; Lahtela, JT; Malminiemi, K, 1995) |
| "The effects of a vasodilating beta-blocker, celiprolol, on insulin sensitivity and cardiovascular risk factors were compared with those of another beta1-selective adrenoceptor blocker, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors." | 5.08 | Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents. ( Ala-Kaila, K; Huupponen, R; Lahtela, J; Malminiemi, K; Malminiemi, O, 1998) |
| "The effects of celiprolol 200 mg or 400 mg once daily on blood pressure (BP), serum lipids, plasma fibrinogen and airways function was compared with the effects of metoprolol 100 mg or 200 mg once daily in 171 patients with mild to moderate hypertension and coexistent hyperlipidaemia in a double-blind, multicentre study lasting 1 year." | 5.08 | Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives: a randomised double-blind long-term parallel group trial. ( Feely, J; Holden, RD; Johnston, GD; Radley, DR; Vyssoulis, G, 1995) |
| "The hemodynamic effects of celiprolol (CAS 56980-93-9), a betablocker with beta 1 antagonist and beta 2 agonist properties, were compared with those of atenolol (CAS 29122-68-7) in 12 patients with mild to moderately severe hypertension (diastolic BP 95-110 mmHg)." | 5.08 | Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension. ( Mahler, F; Saner, H; Seiler, A, 1995) |
| " Therefore, the changes of haemostasis parameters in 22 patients with essential hypertension under long-term celiprolol therapy (> 2 months) were of interest." | 5.08 | Effect of long-term celiprolol therapy on haemostasis in essential hypertension. ( Kratochvílová, H; Okrucká, A; Pechán, J, 1995) |
| " To test whether this criterion is fulfilled by celiprolol, a new beta 1-selective adrenergic blocker drug with peripheral vasodilating activity, we examined the effects of its oral administration on cardiovascular reactivity to laboratory stressors in 18 patients with essential hypertension, according to a placebo-controlled crossover design." | 5.07 | Effects of celiprolol on cardiovascular reactivity to laboratory stressors in patients with hypertension. ( Cardillo, C; De Felice, F; Degen, C; Folli, G, 1992) |
| "The immediate and short-term (2 week) hemodynamic and humoral effects of the beta-1 antagonist, beta-2 agonist, celiprolol, were compared with those of more prolonged atenolol therapy in 12 patients with essential hypertension." | 5.07 | Hemodynamic effects of celiprolol in essential hypertension. ( Frohlich, ED; Kaesser, UR; Ketelhut, R; Losem, CJ; Messerli, FH, 1991) |
| "We tried to assess the antihypertensive effectivity of a betablocker, celiprolol, in the control of mild to moderate essential arterial hypertension." | 5.07 | [Double blind comparative randomized study of the efficacy of celiprolol versus amiloride-hydrochlorothiazide in mild to moderate AHT]. ( Hoyos Jiménez, M; Justo Alpañés, E; Miranda García, MJ; Oliván Martínez, J; Pérez Cano, R, 1993) |
| "A two-centre, double-blind, placebo controlled, randomized 3-way crossover study was undertaken to assess the efficacy, tolerability and safety of celiprolol in mild to moderate essential hypertension." | 5.06 | A multi-centre, placebo controlled comparative study between 200 mg and 400 mg celiprolol in patients with mild to moderate essential hypertension. ( Ankier, SI; Latta, D; Little, PS; Parsley, J; Quail, D; Trafford, JA, 1989) |
| "The antihypertensive effects of equivalent beta-blocking doses of atenolol and celiprolol were compared in 55 patients with mild to moderate hypertension." | 5.06 | A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension. ( Rosenthal, F; Silke, B; Taylor, S, 1986) |
| "A randomized double-blind study compared the antihypertensive efficacy of single daily oral doses of celiprolol 200 or 400 mg to twice daily doses of propranolol 40 or 80 mg in 58 patients with uncomplicated essential hypertension (supine diastolic blood pressure range 95-114 mm Hg)." | 5.06 | Celiprolol in the treatment of hypertension: a comparison with propranolol. ( Beattie, A; Silke, B; Taylor, SH, 1986) |
| "The bronchopulmonary effects of celiprolol were studied in 12 male asthmatic patients who showed mean maximum changes of -24% in forced one-second expiratory volume (FEV1) and 130% in airways resistance (Raw) following a single, 80 mg dose of propranolol." | 5.06 | Bronchosparing properties of celiprolol, a new beta 1, alpha 2-blocker, in propranolol-sensitive asthmatic patients. ( Applin, WJ; Braig, H; Doshan, HD; Matthys, H; Pohl, M; Rühle, KH, 1986) |
| "The safety and efficacy of orally administered celiprolol, a new beta 1-selective adrenergic blocking drug with peripheral beta 2-agonist properties, were assessed in 91 patients with mild to moderate systemic hypertension (supine diastolic blood pressure [BP] 95 to 114 mm Hg without medication) using a placebo-controlled, double-blind, randomized, titration-to-effect study design." | 5.06 | Celiprolol in systemic hypertension. ( Flamenbaum, W; Frishman, WH; Godfrey, JC; Greenberg, S; Lazar, E; Neri, GS; Schoenberger, J; Schwartz, GL; Stevenson, A; Vidt, DG, 1989) |
| "The metabolic effects of celiprolol, a new beta-adrenoceptor blocking agent with intrinsic sympathomimetic activity and alpha 2-blocking properties, were evaluated in a series of patients with hypertension, both with and without hyperlipidemia." | 5.06 | Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol. ( Cremoncini, M; Dujovne, CA; Gianfranceschi, G; Johnson, B; Montanari, G; Sirtori, CR; Sirtori, M; Vaccarino, V, 1989) |
| "5 mg chlorthalidone on uric acid and electrolyte metabolism was investigated in 22 hypertensive patients with gout in a randomized trial." | 5.06 | [Uricosuric action of a new beta receptor blocker-diuretic drug combination]. ( Brandstetter, G; Eslaminejad, S; Hoffmann, H; Maderbacher, H, 1986) |
| "In a 12-month study of 12 patients with essential hypertension treated with once-daily celiprolol, 200 mg, mean supine blood pressure was reduced from 162/102 to 134/84 mm Hg (p less than 0." | 5.06 | A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors. ( Herrmann, JM; Mayer, EO, 1988) |
| "The effects of two cardioselective beta-adrenergic blocking agents--celiprolol (claimed to have bronchodilator properties) and atenolol (without such claims)--on respiratory function and control of asthma were studied in ten asthmatic patients with mild to moderate essential hypertension." | 5.06 | Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension. ( Bateman, ED; Jennings, AA; Opie, LH; van Zyl, AI, 1989) |
| "The results of an extensive pre-clinical and clinical research programme indicate that celiprolol is a safe and effective treatment for both hypertension and angina pectoris." | 5.06 | Celiprolol--overview of 6 years of clinical trials experience. ( Hagen, NS; Lamon, KD; Pruss, TP, 1988) |
| "To evaluate the humoral and hemodynamic (both systemic and renal) effects of celiprolol and to assess whether these effects are at least partially due to the activation of dopamine (DA) receptors, 9 out-patients with mild to moderate uncomplicated essential hypertension, without any therapy for at least 3 weeks, received celiprolol (400 mg once daily) and placebo, each for 1 month, according to a double-blind randomized trial pattern." | 5.06 | Systemic and renal hemodynamic effects of celiprolol in essential hypertensives. ( Lucarini, AR; Salvetti, A, 1988) |
| " In two, randomized, placebo-controlled, 5-way crossover trials, the pulmonary effects of celiprolol 200 and 400 mg, propranolol 40 mg and atenolol 100 mg were compared in 34 asthmatic patients." | 5.06 | Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients. ( Applin, WJ; Brown, R; Caruso, FS; Doshan, HD; Rosenthal, RR; Slutsky, A, 1986) |
| "Previous studies have shown that single dose or short-term administration of celiprolol does not impair pulmonary function in patients with asthma." | 5.06 | Effect of long-term treatment with celiprolol on pulmonary function in a group of mild hypertensive asthmatics. ( Clauzel, AM; Etienne, R; Jean, T; Michel, F; Visier, S, 1988) |
| "In series of 20 patients suffering from atrial arrhythmias, hypertension or hyperkinetic heart syndrome in euthyroid subjects the effect of the new cardioselective beta-blocker celiprolol was examined when orally administered in doses of 300 mg per day against propranolol in a dosage of 160 mg per day." | 5.05 | [Effect of celiprolol compared to propranolol on thyroid metabolism]. ( Eber, O; Langsteger, W; Lind, P, 1985) |
| "The cardiovascular effects of celiprolol in healthy subjects and in those with cardiovascular disease and hypertension are reviewed." | 4.77 | The central and peripheral hemodynamics of celiprolol. ( Mancia, G, 1988) |
| "It is suggested that the IL-6-modulating properties of celiprolol could provide additional value to the therapeutic effectiveness of the drug in the treatment of hypertension." | 3.80 | The effects of celiprolol on serum concentrations of proinflammatory cytokines in hypertensive (SHR) and normotensive (WKY) rats. ( Andrzejczak, D; Górska, D, 2014) |
| "Celiprolol is a hydrophilic, beta 1-selective adrenoceptor antagonist with mild selective beta 2-agonist as well as weak vasodilator properties." | 3.77 | Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. ( Buckley, MM; Milne, RJ, 1991) |
| " The results demonstrated a wide margin of safety for celiprolol over the recommended dosage range of 200 to 600 mg once daily." | 3.76 | Safety profile of celiprolol. ( Lamon, KD, 1988) |
| " Celiprolol decreases oxidative stress in hypertension in vivo and improves EPC numbers and function." | 3.74 | Effects of the antioxidative beta-blocker celiprolol on endothelial progenitor cells in hypertensive rats. ( Fukuda, N; Han, Y; Katakawa, M; Kobayashi, N; Matsumoto, K; Matsumoto, T; Ueno, T; Yamamoto, C; Yao, EH, 2008) |
| " Celiprolol (DOCA-CEL, n = 9, 10 mg/kg per day, subdepressor dose) or a vehicle (DOCA-V, n = 9) were given after induction of DOCA-salt hypertension for 5 weeks, and age-matched sham-operated rats (ShC, n = 9) served as a control group." | 3.71 | Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodeling in deoxycorticosterone acetate-salt hypertensive rats. ( Kobayashi, N; Matsuoka, H; Mori, Y; Nakano, S; Shirataki, H; Tsubokou, Y, 2001) |
| "The authors investigated in 18 patients with essential hypertension the action of celiprolol (usually in combination with a diuretic) on the glucose and lipid metabolism in an open three-month trial." | 3.70 | [Celiprolol improves glucose metabolism in essential hypertension]. ( Dzúrik, R; Fedelesová, V; Oksa, A; Spustová, V, 1998) |
| "The aim of this study was to evaluate the long-term effects of the selective beta 1-blocker/beta 2-agonist celiprolol on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension." | 3.70 | Effect of the beta 1-blocker/beta 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. ( Dadoush, G; Haldoupi, M; Kanonidis, I; Karamouzis, M; Kokkas, B; Kotridis, P; Papadopoulos, CL; Platis, A, 1998) |
| "This study compares the antihypertensive and lipid modifying effects of treatment of mild to moderate hypertension with celiprolol or atenolol." | 3.69 | A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients. ( Jackson, RT; Milne, RJ; Vander Hoorn, S, 1997) |
| "In 30 hypertensives with angina pectoris the acute action of beta-blockers Celiprolol and Metoprolol on the global and coronary haemodynamics was tested within cardiac catheter diagnostics." | 3.68 | [Acute changes of coronary and global hemodynamics in patients with angina pectoris and arterial hypertension caused by celiprolol and metoprolol]. ( Bruch, L; Franz, N; Gola, G; Heublein, B; Linss, G; Modersohn, D; Walde, T, 1990) |
| "5 years) with essential hypertension (WHO stages I-II) who were treated with celiprolol for 4 weeks, and in 12 patients (mean age: 39." | 3.67 | Lipid profile improvement following celiprolol. ( Freischütz, G; Herrmann, JM; von Heyman, F, 1988) |
| "Long-term treatment with celiprolol, a new cardioselective beta blocker, significantly reduced blood pressure in 14 patients with essential hypertension (World Health Organization stages I to II)." | 3.67 | Reduction of left ventricular hypertrophy in hypertensive patients after treatment with celiprolol. ( Bischof, F; Burghagen, H; Freischuetz, G; Herrmann, JM; Mayer, EO; Von Heymann, F, 1988) |
| "Arterial blood pressure and central hemodynamic changes were assessed in 44 patients with essential hypertension, uncontrollable by prazosin alone, after propranolol (anaprilin), celiprolol, clonidine (clofelin) or verapamil were added to the treatment schedule." | 3.67 | [Hemodynamic effect of a combination of prazosin with cardiac depressants in the treatment of hypertension]. ( Akopian, LM; Basem, AS; Ivleva, AIa; Krasnobaeva, GM; Moiseev, VS, 1988) |
| "To evaluate the humoral and hemodynamic (both systemic and renal) effects of chronic treatment with celiprolol, six out-patients with mild to moderate uncomplicated essential hypertension received placebo for 1 month and celiprolol (400 mg qid) for 6 months." | 3.67 | Long-term humoral and hemodynamic effects of celiprolol. ( Lucarini, AR; Palmieri, L; Salvetti, A; Simonini, N, 1988) |
| "Celiprolol hydrochloride is a new highly cardioselective vasodilating beta-adrenoceptor antagonist that has been proven effective and safe for the treatment of essential hypertension." | 2.67 | Clinical safety and efficacy of celiprolol. ( Lamon, KD, 1991) |
| "Celiprolol is a 'third generation' beta-blocking agent which is claimed to avoid problems associated with simpler beta-blockers, such as vasoconstriction, bronchoconstriction and myocardial depression." | 2.67 | Acute haemodynamic profile of celiprolol in patients with coronary heart disease and hypertension: a double-blind comparison with metoprolol. ( Franz, N; Heublein, B; Modersohn, D; Panzner, B, 1991) |
| "Celiprolol is a new generation beta blocker with a novel profile of activity that includes a high degree of cardioselectivity, partial beta 2-agonist activity, and possibly a degree of direct peripheral vasodilation." | 2.66 | Antihypertensive therapy with celiprolol: a new cardioselective beta blocker. ( Norris, RJ, 1988) |
| "The effect of celiprolol at a daily dosage of 300 mg (19 patients) was compared with that of propranolol at a daily dosage of 120 mg (14 patients) on peripheral blood flow of the calf and foot in a randomized double-blind trial." | 2.66 | [Comparative studies of the effect of a cardioselective and a noncardioselective beta-blocker on peripheral circulation in patients with arterial occlusive disease]. ( Klieber, M; Resch, F, 1986) |
| " This dosing schedule can therefore be regarded as appropriate for antihypertensive therapy." | 2.66 | Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring. ( Casadei, R; Mancia, G; Parati, G; Pomidossi, G; Ravogli, A; Trazzi, S; Zanchetti, A, 1988) |
| " The decrease in diastolic blood pressure at the end of the second week was significantly correlated with the reciprocal of the plasma celiprolol concentration at steady-state at the end of the dosage interval." | 2.66 | Comparison of the antihypertensive effects of celiprolol and acebutolol. ( Belovezhdov, N; Gerova, Z; Terziivanov, D; Vlahov, V, 1988) |
| "Celiprolol is a newly developed cardioselective beta-blocking agent with mild beta 2-agonist and weak alpha 2-antagonist properties." | 2.66 | Effects of celiprolol on plasma renin, aldosterone, norepinephrine and epinephrine in primary hypertension. ( DeQuattro, V; Hernandez, PH; Kimura, S; Lee, DD, 1988) |
| "Celiprolol was compared with chlorthalidone, an antihypertensive drug without known effect on bronchial tone." | 2.66 | A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction. ( Capone, P; Clauzel, AM; Dorow, P; Mathieu, M; Mayol, R, 1986) |
| "Celiprolol was compared with chlorthalidone in a double-blind randomized placebo-controlled study of 30 hypertensive or anginal patients with reversible bronchial obstruction." | 2.66 | Celiprolol--review of airways studies. ( Dorow, P, 1988) |
| "Celiprolol has shown equivalent antihypertensive efficacy to other beta-blockers, notably propranolol, atenolol, metoprolol and pindolol, in patients aged 18 to 75 years with mild to moderate essential hypertension." | 2.39 | Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. ( Dunn, CJ; Spencer, CM, 1995) |
| "Celiprolol hydrochloride is a cardioselective beta 1-adrenergic antagonist with partial agonist activity." | 2.38 | Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly. ( Lamon, KD, 1991) |
| "We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta-blocker, celiprolol." | 2.38 | Celiprolol pneumonitis. ( Bonnotte, B; Camus, P; Foucher, P; Jeannin, L; Lombard, JN; Maynadie, M; Reybet Degat, O, 1993) |
| "The drug has a place in the chronic treatment of hypertension and in the therapy of hypertensive emergencies." | 2.38 | Clinical experience with dual-acting drugs in hypertension. ( Rahn, KH, 1992) |
| "Celiprolol is a new 'cardioselective' beta-adrenoceptor blocking drug with intrinsic sympathomimetic (partial agonist) activity and a weak vasodilating effect." | 2.37 | Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. ( Brogden, RN; Riddell, JG; Shanks, RG, 1987) |
| "Carvedilol is a new compound that combines beta-receptor blockade and vasodilation in one molecule." | 2.37 | Antihypertensive compounds with combined actions. ( Rahn, KH, 1987) |
| " Therefore, they should not have adverse bronchial effects and could even have a slight bronchodilator activity." | 1.31 | [Safety and efficacy of celiprolol in hypertensive patients with chronic obstructive lung disease]. ( Bravo, C; Chahuán, M; Corradi, L; Román, O, 2000) |
| "Treatment with celiprolol was not associated with considerable heart rate decrease or changes of stroke volume and cardiac output." | 1.31 | [Use of selective long-acting beta-blocker with vasodilating activity celiprolol in patients with essential hypertension]. ( Mozharova, LG; Podzolkov, VI, 2002) |
| "Essential hypertension is associated with an increased incidence of insulin resistance of skeletal muscle glucose transport." | 1.30 | The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats. ( Dietze, GJ; Fogt, DL; Henriksen, EJ; Jacob, S, 1999) |
| "Celiprolol was administered orally in the daily dose of 300 mg." | 1.29 | [Celiprolol increases the microcirculation in subcutaneous tissue and calf muscles in essential hypertension]. ( Balazovjech, I; Cesnaková, Z; Pechán, J, 1993) |
| "Celiprolol (C) is a new selective beta 1-blocker with partial beta 2-agonistic activity." | 1.28 | Short-term effects of celiprolol on blood pressure and left ventricular performance in hypertensive cardiomyopathy. ( Alay, D; Cuenca, P; Lorenzo, JG; Plaza, L; Rodríguez Rodrigo, FJ; Ruiz, I; Terol, I, 1992) |
| "Hypertension was known for more than 1 year in 57%, for even more than 5 years in 28%." | 1.27 | [Results of the selectol field study in Austria]. ( Hoffman, H; Hoffman, W, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 65 (45.77) | 18.7374 |
| 1990's | 58 (40.85) | 18.2507 |
| 2000's | 16 (11.27) | 29.6817 |
| 2010's | 3 (2.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrzejczak, D | 1 |
| Górska, D | 1 |
| Eguchi, K | 1 |
| Hoshide, S | 1 |
| Kario, K | 1 |
| Yao, EH | 1 |
| Fukuda, N | 1 |
| Matsumoto, T | 1 |
| Katakawa, M | 1 |
| Yamamoto, C | 1 |
| Han, Y | 1 |
| Ueno, T | 1 |
| Kobayashi, N | 4 |
| Matsumoto, K | 1 |
| Mizuta, E | 1 |
| Utami, SB | 1 |
| Ohtahara, A | 1 |
| Endo, S | 1 |
| Mishima, M | 1 |
| Hasegawa, A | 1 |
| Yamada, K | 1 |
| Kato, M | 1 |
| Yamamoto, K | 2 |
| Ogino, K | 1 |
| Ninomiya, H | 1 |
| Miyazaki, S | 1 |
| Hamada, T | 1 |
| Taniguchi, SI | 1 |
| Cheng, J | 1 |
| Hisatome, I | 1 |
| Tsubokou, Y | 3 |
| Mita, S | 2 |
| Yoshida, K | 2 |
| Matsuoka, H | 3 |
| Podzolkov, VI | 1 |
| Mozharova, LG | 1 |
| Bozec, E | 1 |
| Fassot, C | 1 |
| Tropeano, AI | 2 |
| Boutouyrie, P | 3 |
| Jeunemaitre, X | 1 |
| Lacolley, P | 1 |
| Dabire, H | 1 |
| Laurent, S | 3 |
| Pogosova, GV | 1 |
| Zhidko, NI | 1 |
| Mikheeva, TG | 1 |
| Gudkova, OA | 1 |
| Tikhomirova, EA | 1 |
| Honda, T | 1 |
| Kobayashi, T | 1 |
| Hara, K | 1 |
| Nakano, S | 2 |
| Vyssoulis, GP | 4 |
| Marinakis, AG | 1 |
| Aznaouridis, KA | 1 |
| Karpanou, EA | 3 |
| Arapogianni, AN | 1 |
| Cokkinos, DV | 1 |
| Stefanadis, CI | 1 |
| Ikeda, K | 1 |
| Kashihara, H | 1 |
| Hosozawa, KI | 1 |
| Tamura, M | 1 |
| Baba, S | 1 |
| Iwasaki, Y | 1 |
| Olkinuora, JT | 1 |
| Viikari, J | 1 |
| Vanhanen, H | 1 |
| Makkonen, N | 1 |
| Kalliomäki, T | 1 |
| Rameis, H | 1 |
| Brandstetter, G | 2 |
| Hoffmann, H | 6 |
| Arita, M | 1 |
| Horinaka, S | 2 |
| Komatsu, K | 1 |
| Frohlich, ED | 4 |
| Mehta, JL | 1 |
| Lopez, LM | 1 |
| Chen, L | 1 |
| Cox, OE | 1 |
| Malminiemi, K | 4 |
| Lahtela, JT | 1 |
| Huupponen, R | 2 |
| Valiouli, MA | 2 |
| Toutouzas, PK | 3 |
| Johnston, GD | 1 |
| Vyssoulis, G | 1 |
| Feely, J | 1 |
| Holden, RD | 1 |
| Radley, DR | 1 |
| Kouremetis, MT | 1 |
| Michaelides, AP | 1 |
| Modersohn, D | 3 |
| Franz, N | 3 |
| Heublein, B | 3 |
| Panzner, B | 2 |
| Walde, T | 2 |
| Bruch, L | 2 |
| Lijnen, P | 2 |
| Van Hoof, R | 2 |
| Amery, A | 2 |
| Rueckert, PA | 1 |
| Slane, PR | 1 |
| Hanson, P | 1 |
| Lombard, JN | 1 |
| Bonnotte, B | 1 |
| Maynadie, M | 1 |
| Foucher, P | 1 |
| Reybet Degat, O | 1 |
| Jeannin, L | 1 |
| Camus, P | 1 |
| Dujovne, CA | 2 |
| Eff, J | 1 |
| Ferraro, L | 1 |
| Goldstein, RJ | 1 |
| Gotto, AM | 1 |
| Hall, WD | 1 |
| Harris, WS | 1 |
| Held, SJ | 1 |
| Herd, A | 1 |
| Hunninghake, DB | 1 |
| Pechán, J | 3 |
| Cesnaková, Z | 1 |
| Balazovjech, I | 2 |
| Okrucká, A | 2 |
| Kofahl, B | 1 |
| Henke, D | 1 |
| Hettenbach, A | 1 |
| Mutschler, E | 1 |
| Oliván Martínez, J | 1 |
| Hoyos Jiménez, M | 1 |
| Miranda García, MJ | 1 |
| Justo Alpañés, E | 1 |
| Pérez Cano, R | 1 |
| Haneda, T | 2 |
| Okamoto, K | 1 |
| Hiroshima, T | 1 |
| Kashiwagi, Y | 1 |
| Miyata, S | 1 |
| Ohi, S | 1 |
| Nakamura, Y | 1 |
| Osaki, J | 1 |
| Hirayama, T | 1 |
| Ogawa, Y | 2 |
| Kratochvílová, H | 1 |
| Saner, H | 1 |
| Seiler, A | 1 |
| Mahler, F | 1 |
| Dunn, CJ | 1 |
| Spencer, CM | 1 |
| Cleophas, TJ | 3 |
| van der Mey, N | 1 |
| van der Meulen, J | 2 |
| Niemeyer, MG | 2 |
| Tolvanen, JP | 1 |
| Wu, X | 1 |
| Kähönen, M | 1 |
| Sallinen, K | 1 |
| Mäkynen, H | 1 |
| Pekki, A | 1 |
| Pörsti, I | 1 |
| Lahtela, J | 1 |
| Malminiemi, O | 1 |
| Ala-Kaila, K | 1 |
| Van Mieghem, W | 2 |
| Oksa, A | 1 |
| Fedelesová, V | 1 |
| Spustová, V | 1 |
| Dzúrik, R | 1 |
| Papadopoulos, CL | 1 |
| Kokkas, B | 1 |
| Kotridis, P | 1 |
| Karamouzis, M | 1 |
| Haldoupi, M | 1 |
| Platis, A | 1 |
| Dadoush, G | 1 |
| Kanonidis, I | 1 |
| Kakoki, M | 1 |
| Hirata, Y | 1 |
| Hayakawa, H | 1 |
| Nishimatsu, H | 1 |
| Suzuki, Y | 1 |
| Nagata, D | 1 |
| Suzuki, E | 1 |
| Kikuchi, K | 2 |
| Nagano, T | 1 |
| Omata, M | 1 |
| Milne, RJ | 2 |
| Vander Hoorn, S | 1 |
| Jackson, RT | 1 |
| Fogari, R | 3 |
| Zoppi, A | 3 |
| Corradi, L | 2 |
| Preti, P | 1 |
| Mugellini, A | 1 |
| Lusardi, P | 1 |
| Jacob, S | 1 |
| Fogt, DL | 1 |
| Dietze, GJ | 1 |
| Henriksen, EJ | 1 |
| Planès, C | 1 |
| Foucher, A | 1 |
| Leroy, M | 1 |
| Dartois, N | 3 |
| Juste, K | 1 |
| Baillart, O | 1 |
| Raffestin, B | 1 |
| vd Mey, N | 1 |
| Meulen, J | 1 |
| van de Luit, L | 1 |
| Zwinderman, AH | 1 |
| Bussy, C | 2 |
| Hayoz, D | 2 |
| Hengstler, J | 2 |
| Laloux, B | 2 |
| Brunner, H | 2 |
| Chahuán, M | 1 |
| Román, O | 2 |
| Bravo, C | 1 |
| Kato, J | 1 |
| Matsuhashi, H | 1 |
| Morimoto, H | 1 |
| Honda, H | 1 |
| Takenaka, T | 1 |
| Tanazawa, S | 1 |
| Kataoka, R | 1 |
| Mori, Y | 1 |
| Shirataki, H | 1 |
| Totsuka, M | 1 |
| Miyashita, Y | 1 |
| Ito, Y | 1 |
| Oyama, T | 1 |
| Hashiguti, S | 1 |
| Watanabe, H | 1 |
| Shirai, K | 1 |
| Ban, T | 1 |
| Ishihara, H | 1 |
| Kawano, E | 1 |
| Mori, J | 1 |
| Kanechi, M | 1 |
| Rodríguez Rodrigo, FJ | 1 |
| Ruiz, I | 1 |
| Lorenzo, JG | 1 |
| Alay, D | 1 |
| Terol, I | 1 |
| Cuenca, P | 1 |
| Plaza, L | 1 |
| Thom, S | 1 |
| Hughes, A | 1 |
| Schachter, M | 1 |
| Sever, P | 1 |
| Dickinson, R | 1 |
| Horobin, J | 1 |
| Rahn, KH | 2 |
| Pitsavos, CE | 1 |
| Kourtis, TK | 1 |
| Paleologos, AA | 1 |
| Iagenskiĭ, AV | 1 |
| Barsukov, BP | 1 |
| Desager, JP | 1 |
| Harvengt, C | 1 |
| Fagard, R | 1 |
| Peerenboom, P | 1 |
| Staessen, J | 1 |
| Thijs, L | 1 |
| Cardillo, C | 1 |
| Degen, C | 1 |
| De Felice, F | 1 |
| Folli, G | 1 |
| Frishman, WH | 2 |
| Taylor, SH | 4 |
| Norris, RJ | 2 |
| Lamon, KD | 4 |
| Ketelhut, R | 1 |
| Kaesser, UR | 1 |
| Losem, CJ | 1 |
| Messerli, FH | 1 |
| Lobos Bejarano, JM | 1 |
| Granados Menéndez, MI | 1 |
| del Valle González, J | 1 |
| Bravo Juega, P | 1 |
| Buckley, MM | 1 |
| Tettamanti, F | 2 |
| Malamani, G | 1 |
| Pasotti, C | 1 |
| Poletti, L | 1 |
| Rizzardi, G | 1 |
| Fiocchi, G | 1 |
| Linss, G | 1 |
| Gola, G | 1 |
| Kapitanenko, AM | 1 |
| Dulin, PA | 1 |
| Meza, N | 1 |
| Klenner, C | 1 |
| Dorow, P | 3 |
| Clauzel, AM | 2 |
| Capone, P | 8 |
| Mayol, R | 5 |
| Mathieu, M | 3 |
| Doshan, HD | 2 |
| Rosenthal, RR | 1 |
| Brown, R | 1 |
| Slutsky, A | 1 |
| Applin, WJ | 2 |
| Caruso, FS | 2 |
| Estes, NA | 1 |
| Lin, SK | 1 |
| Solomon, TA | 1 |
| Silke, B | 3 |
| Rosenthal, F | 2 |
| Taylor, S | 2 |
| Beattie, A | 2 |
| Matthys, H | 1 |
| Rühle, KH | 1 |
| Braig, H | 1 |
| Pohl, M | 1 |
| Opie, LH | 3 |
| Mancia, G | 5 |
| Grassi, G | 1 |
| Parati, G | 4 |
| Pomidossi, G | 3 |
| Sabadini, E | 1 |
| Giannattasio, C | 1 |
| Bolla, G | 1 |
| Zanchetti, A | 2 |
| Hoffmann, W | 2 |
| Schindl, R | 1 |
| Würtz, J | 1 |
| Ravogli, A | 3 |
| Bragato, R | 1 |
| Omboni, S | 1 |
| Mutti, E | 2 |
| Flamenbaum, W | 1 |
| Schoenberger, J | 1 |
| Schwartz, GL | 1 |
| Vidt, DG | 1 |
| Neri, GS | 1 |
| Greenberg, S | 1 |
| Lazar, E | 1 |
| Godfrey, JC | 1 |
| Stevenson, A | 1 |
| Trafford, JA | 1 |
| Latta, D | 1 |
| Little, PS | 1 |
| Parsley, J | 1 |
| Ankier, SI | 1 |
| Quail, D | 1 |
| van Zyl, AI | 1 |
| Jennings, AA | 1 |
| Bateman, ED | 1 |
| Sirtori, CR | 1 |
| Johnson, B | 1 |
| Vaccarino, V | 1 |
| Montanari, G | 1 |
| Cremoncini, M | 1 |
| Gianfranceschi, G | 1 |
| Sirtori, M | 1 |
| Hitzenberger, G | 1 |
| Leary, P | 1 |
| Stumpe, K | 1 |
| Kolloch, R | 1 |
| Langsteger, W | 1 |
| Lind, P | 1 |
| Eber, O | 1 |
| Belovezhdov, N | 3 |
| Nachev, Ch | 1 |
| Angelova, I | 1 |
| Gergova, V | 1 |
| Stefanov, G | 2 |
| Maderbacher, H | 1 |
| Eslaminejad, S | 1 |
| Trimarco, B | 2 |
| Lembo, G | 2 |
| De Luca, N | 1 |
| Ricciardelli, B | 2 |
| Rosiello, G | 2 |
| Volpe, M | 2 |
| Orofino, G | 2 |
| Condorelli, M | 2 |
| Riddell, JG | 1 |
| Shanks, RG | 1 |
| Brogden, RN | 1 |
| Herrmann, JM | 4 |
| Mayer, EO | 2 |
| McInnes, GT | 1 |
| McLenachan, JM | 1 |
| Henderson, E | 1 |
| Herrick, AL | 1 |
| Dargie, HJ | 1 |
| Pruss, TP | 1 |
| Hagen, NS | 1 |
| von Heyman, F | 1 |
| Freischütz, G | 1 |
| DeLuca, N | 1 |
| Ghiringhelli, S | 1 |
| Cozzi, E | 1 |
| Tsialtas, D | 1 |
| Widimský, J | 1 |
| Lefflerová, K | 1 |
| Hoffman, W | 1 |
| Hoffman, H | 1 |
| Klebel, E | 1 |
| Saam, R | 1 |
| Klieber, M | 1 |
| Resch, F | 1 |
| Vlakhov, N | 1 |
| Terziivanov, D | 2 |
| Koĭchev, A | 1 |
| Casadei, R | 2 |
| Trazzi, S | 2 |
| Bischof, F | 2 |
| Von Heymann, F | 2 |
| Freischuetz, G | 2 |
| Burghagen, H | 2 |
| Lucarini, AR | 2 |
| Salvetti, A | 2 |
| Moiseev, VS | 1 |
| Ivleva, AIa | 1 |
| Akopian, LM | 1 |
| Krasnobaeva, GM | 1 |
| Basem, AS | 1 |
| Vlahov, V | 1 |
| Gerova, Z | 1 |
| Simonini, N | 1 |
| Palmieri, L | 1 |
| Kimura, S | 1 |
| DeQuattro, V | 1 |
| Hernandez, PH | 1 |
| Lee, DD | 1 |
| Valentin, A | 1 |
| Karnik, R | 1 |
| Kaspar, L | 1 |
| Slany, J | 1 |
| Jean, T | 1 |
| Etienne, R | 1 |
| Visier, S | 1 |
| Michel, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients[NCT01157234] | Phase 4 | 32 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury). (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -0.66 |
| Metoprolol | -2.35 |
The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | 2.16 |
| Metoprolol | 10.43 |
"Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.~Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure" (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, Mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -1.07 |
| Metoprolol | -3.19 |
Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | -8.14 |
| Metoprolol | 8.70 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol < 50 Years Old | 51.55 |
| Metoprolol <50 Years Old | -16.64 |
(NCT01157234)
Timeframe: Baseline and Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol <50 Year Old | 51.55 |
| Metoprolol >/= 50 Year Old | -17.99 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol >/=50 Years Old | -15.25 |
| Metoprolol >/=50 Years Old | -17.99 |
(NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol >/=50 Years Old | -15.25 |
| Metoprolol <50 Years Old | -16.64 |
(NCT01157234)
Timeframe: 12 Months
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Nebivolol | 50.07 |
| Metoprolol | 38.13 |
Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L. (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Nebivolol | 11.47 |
| Metoprolol | -17.27 |
Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level (NCT01157234)
Timeframe: Change in Baseline, Month-12
| Intervention | millimeter, Mercury (Least Squares Mean) |
|---|---|
| Nebivolol | -2.65 |
| Metoprolol | -3.88 |
20 reviews available for celiprolol and Hypertension
| Article | Year |
|---|---|
Celiprolol pneumonitis.
Topics: Adrenergic beta-Antagonists; Alveolitis, Extrinsic Allergic; Celiprolol; Humans; Hypertension; Lung; | 1993 |
Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.
Topics: Administration, Oral; Angina Pectoris; Antihypertensive Agents; Celiprolol; Humans; Hypertension; Ra | 1995 |
Clinical experience with dual-acting drugs in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Celipr | 1992 |
Celiprolol--a better beta blocker?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Circulation; Celiprolol; Humans; Hyperte | 1992 |
[The third generation of b-blockers: new possibilities ].
Topics: Adrenergic beta-Antagonists; Asthma; Celiprolol; Hemodynamics; Humans; Hypertension; Lipoproteins, H | 1992 |
Clinical perspective on celiprolol: cardioprotective potential.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Asthma; Blood Pressure; Celiprolol; Coronary Disease; | 1991 |
Vasodilatory beta-blockers: systemic and regional hemodynamic effects.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Celiprolol; Drug Administration S | 1991 |
Efficacy of celiprolol in hypertension and angina pectoris. Introduction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Celiprolol; Humans; Hypertens | 1991 |
Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Celiprolol; Humans; Hypertension; Product Surveillance, Po | 1991 |
Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Antihypertensive Agents; Celiprolol; Dogs; He | 1991 |
[Adrenergic beta receptor blockader celiprolol in the treatment of patients with arterial hypertension].
Topics: Adult; Aged; Celiprolol; Clinical Trials as Topic; Drug Evaluation; Female; Hemodynamics; Humans; Hy | 1990 |
Effects of celiprolol on reflex control of the cardiovascular system in essential hypertension.
Topics: Acebutolol; Adrenergic beta-Antagonists; Animals; Cardiovascular Physiological Phenomena; Cardiovasc | 1986 |
Antihypertensive compounds with combined actions.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Celiprolol; Humans; Hy | 1987 |
Clinical and hemodynamic effects of celiprolol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Celiprolol; Hemodynamics; Humans; Hypertension; Propanolamines | 1989 |
Celiprolol and risk factor reversal in hypertension.
Topics: Adrenergic beta-Antagonists; Celiprolol; Humans; Hypertension; Propanolamines; Risk Factors | 1989 |
Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Celiprolol; Hemodynamics; Humans; Hypertensio | 1987 |
The central and peripheral hemodynamics of celiprolol.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Celiprolol; Coronary Disease; Hemodynamics; Hu | 1988 |
Celiprolol in hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1988 |
Safety profile of celiprolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Atenolol; Celiprolol; Chlorth | 1988 |
Betablockers in the treatment of hypertension (with special emphasis on betablockers with ISA). A review.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Celiprolol; Humans; Hypertension; Labetal | 1988 |
82 trials available for celiprolol and Hypertension
| Article | Year |
|---|---|
Effects of Celiprolol and Bisoprolol on Blood Pressure, Vascular Stiffness, and Baroreflex Sensitivity.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Ankle Brachial Index; Antihypertensive Agents; | 2015 |
A vasodilating β1 blocker celiprolol inhibits muscular release of uric acid precursor in patients with essential hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Blood Pressure; Celiprolol; Exercise Test; Female; For | 2013 |
Angiotensinogen gene M235T polymorphism and reduction in wall thickness in response to antihypertensive treatment.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiotensinogen; Antihypertensive Agents; Caro | 2003 |
Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study).
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Celiprolol; Coronary Disease; Drug Therapy, | 2006 |
[Treatment of hypertensive hyperuricemic patients with a new beta blocker-diuretic combination].
Topics: Adult; Aged; Atenolol; Celiprolol; Chlorthalidone; Drug Combinations; Drug Tolerance; Female; Humans | 1984 |
Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol.
Topics: Aged; Amino Acid Oxidoreductases; Celiprolol; Humans; Hypertension; Neutrophils; Nitric Oxide Syntha | 1994 |
Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension.
Topics: Adult; Blood Glucose; Blood Pressure; Celiprolol; Female; Glucose Clamp Technique; Glucose Tolerance | 1995 |
Left ventricular and aortic root structure and function changes with beta blocker antihypertensive therapy. A one-year double blind study of celiprolol and metoprolol.
Topics: Aorta; Celiprolol; Double-Blind Method; Echocardiography, Doppler, Pulsed; Female; Hemodynamics; Hum | 1995 |
Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Glucose; Blood Pressure; Celiprolol; Dru | 1995 |
Effect of celiprolol and metoprolol on lipids, fibrinogen and airways function in hyperlipidaemic hypertensives: a randomised double-blind long-term parallel group trial.
Topics: Adult; Aged; Blood Pressure; Celiprolol; Double-Blind Method; Female; Fibrinogen; Heart Rate; Humans | 1995 |
Effect of beta-blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Celiprolol; Double-Blind Method; Echocardiography; Ele | 1995 |
Acute influence of beta-adrenergic antagonists on left ventricular diastolic function: contrasting results after administration of celiprolol and metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Celiprolol; Coronary Disease; Double-Blind Method; Heart; Humans | 1994 |
Effects of celiprolol vs. nifedipine on serum lipoproteins in patients with mild to moderate hypertension.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins B; Blood Pressure; Celiprolol; | 1994 |
Adding beta-2 agonism does not improve beta-1 blockade exercise responses in hypertensives.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Atenolol; Blood Pressure; Celiprolol; Cross-Over Stud | 1994 |
Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects.
Topics: Adult; Aged; Atenolol; Blood Pressure; Celiprolol; Double-Blind Method; Female; Humans; Hyperlipopro | 1993 |
The effect of short-term celiprolol therapy on platelet function in essential hypertension.
Topics: Adult; beta-Thromboglobulin; Blood Pressure; Celiprolol; Drug Administration Schedule; Female; Human | 1993 |
[Double blind comparative randomized study of the efficacy of celiprolol versus amiloride-hydrochlorothiazide in mild to moderate AHT].
Topics: Adult; Amiloride; Celiprolol; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroc | 1993 |
Effect of long-term celiprolol therapy on haemostasis in essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Coagulation; Celiprolol; Drug Administration Schedule; Female; | 1995 |
Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Celiprolol; Cross-Over Studies; | 1995 |
Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Celiprolol; Double-Blind Method; | 1996 |
Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Celiprolol; Cross-Over Studies; Double-Blind Me | 1998 |
Evaluation of glucose tolerance during treatment with celiprolol in patients with mild arterial hypertension without diabetes mellitus. The Genker General Practitioners.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Glucose; Celiprolol; Female | 1997 |
Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Analysis of Variance; Atenolol; Bisopr | 1999 |
Effect of celiprolol treatment in hypertensive patients with sleep apnea.
Topics: Aged; Antihypertensive Agents; Celiprolol; Female; Heart Rate; Humans; Hypertension; Male; Middle Ag | 1999 |
Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Celiprolol; Double-Blind Method; | 1997 |
Daytime-selective antihypertensive activity of celiprolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting Enzyme | 1999 |
Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group.
Topics: Adrenergic beta-Antagonists; Celiprolol; Fasting; Female; Glucose Tolerance Test; Humans; Hyperlipid | 2000 |
Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Carotid Ar | 2000 |
[Local pulse pressure and regression of arterial wall hypertrophy during antihypertensive treatment. CELIMENE study. The Celiprolol Intima-Media Enalapril Efficacy study].
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihyp | 2000 |
Effect of celiprolol on cardiac hypertrophy in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Celi | 2000 |
[The effect of celiprolol hydrochloride for lipid metabolism--especially for the low density lipoprotein particle size].
Topics: Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Celiprolol; Humans; Hypertension; Lipid | 2001 |
Comparison of the effect of celiprolol and nifedipine on blood pressure and plasma lipids.
Topics: Acyltransferases; Adult; Antihypertensive Agents; Apoproteins; Blood Pressure; Celiprolol; Cholester | 1992 |
Effects of celiprolol on cardiovascular reactivity to laboratory stressors in patients with hypertension.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Celiprolol; Female; Heart Rate | 1992 |
Hemodynamic effects of celiprolol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Celiprolol; Dose-Response Relationship, Drug; Ec | 1991 |
Acute haemodynamic profile of celiprolol in patients with coronary heart disease and hypertension: a double-blind comparison with metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Celiprolol; Coronary Circulation; Coronary Disease; Double-Blind | 1991 |
Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Antihypertensive Agents; Celiprolol; Dogs; He | 1991 |
Clinical safety and efficacy of celiprolol.
Topics: Blood Pressure; Celiprolol; Humans; Hypertension; Propanolamines; Vasodilator Agents | 1991 |
The effect of celiprolol on the blood lipid profile in hypertensive patients with high cholesterol levels.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Celiprolol; Cholesterol; Humans; Hypertens | 1991 |
Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Celiprolol; Forced Expiratory Volume | 1990 |
[Adrenergic beta receptor blockader celiprolol in the treatment of patients with arterial hypertension].
Topics: Adult; Aged; Celiprolol; Clinical Trials as Topic; Drug Evaluation; Female; Hemodynamics; Humans; Hy | 1990 |
Effect of celiprolol on large and small arteries of the forearm circulation in hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Brachial Artery; Celiprolol; Echocardiography, | 1990 |
A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction.
Topics: Adrenergic beta-Antagonists; Asthma; Celiprolol; Chlorthalidone; Clinical Trials as Topic; Double-Bl | 1986 |
Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients.
Topics: Adrenergic beta-Antagonists; Asthma; Atenolol; Celiprolol; Forced Expiratory Volume; Humans; Hyperte | 1986 |
A placebo-controlled double-blind multicenter study of celiprolol in the treatment of mild and moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Celiprolol; Clinical Trials as Topic; Double-Blind Method; Femal | 1986 |
A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Celiprolol; Clinical Trials as Topic; Double-Blind Method; Fe | 1986 |
Celiprolol in the treatment of hypertension: a comparison with propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Celiprolol; Clinical Trials as Topic; Double-Blind Method; | 1986 |
Bronchosparing properties of celiprolol, a new beta 1, alpha 2-blocker, in propranolol-sensitive asthmatic patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Asthma; Celiprolol; Forced Expirat | 1986 |
Results of the Austrian celiprolol postmarketing surveillance study.
Topics: Celiprolol; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Propanolamines; Receptors, | 1986 |
The effect of the cardioselective beta blocker celiprolol on pulmonary function in asthmatic patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Airway Resistance; Asthma; Celiprolol; Female; Forced Expi | 1986 |
Celiprolol in systemic hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Celiprolol; Clinical Trials as Topic; Double-Blind Method; | 1989 |
A multi-centre, placebo controlled comparative study between 200 mg and 400 mg celiprolol in patients with mild to moderate essential hypertension.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Celiprolol; Double-Blind Method; Female; | 1989 |
[The results of a celiprolol drug surveillance study in Spain. The Celiprolol Multicenter Group].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Celiprolol; | 1989 |
Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Asthma; Atenolol; Blood Pressure; Celip | 1989 |
Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Celiprolol; Cholesterol; Chromatography, High Pressure Liq | 1989 |
[Treatment of hypertension with a new beta blocker-diuretic combination under long-term control].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Celiprolol; Chlorthalidone; Clinical Trial | 1985 |
A comparative study of celiprolol and placebo in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Celiprolol; Clinical Trials as Topic; Female; Humans; Hypertension; Mal | 1985 |
A comparison of celiprolol and propranolol in the treatment of hypertension in one hundred and seventy-nine subjects.
Topics: Adrenergic beta-Antagonists; Celiprolol; Clinical Trials as Topic; Double-Blind Method; Humans; Hype | 1985 |
A comparison of celiprolol and atenolol in the treatment of hypertension: a placebo controlled double blind study.
Topics: Adrenergic beta-Antagonists; Atenolol; Celiprolol; Clinical Trials as Topic; Double-Blind Method; Hu | 1985 |
[Effect of celiprolol compared to propranolol on thyroid metabolism].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Celiprolol; Female; Humans; Hypertension; Male; Middle Age | 1985 |
[Clinical studies of celiprolol in the treatment of arterial hypertension].
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Aged; Celiprolol; Clinical Trials as Topic; Double-B | 1985 |
[Uricosuric action of a new beta receptor blocker-diuretic drug combination].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Celiprolol; Chlorthalidone; Clinical Trials as Topic; Diur | 1986 |
Effects of celiprolol on systemic and forearm circulation in hypertensive patients: a double-blind cross-over study versus metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Celiprolol; Double-Blind Method; Echocardiography; Female; Forea | 1987 |
Antihypertensive therapy with celiprolol: a new cardioselective beta blocker.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Celiprolol; Clinical Trials as Topic | 1988 |
A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Celiprolol; Cholesterol | 1988 |
Celiprolol in hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bloo | 1988 |
Celiprolol and verapamil in the treatment of essential hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Celiprolol; Clinical Trials as Topic | 1988 |
Safety profile of celiprolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Atenolol; Celiprolol; Chlorth | 1988 |
Celiprolol--overview of 6 years of clinical trials experience.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Celiprolol; Clinical Trials as Topic; Humans; Hyperten | 1988 |
Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass.
Topics: Adrenergic beta-Antagonists; Adult; Blood Flow Velocity; Blood Pressure; Celiprolol; Clinical Trials | 1988 |
Comparison of the antihypertensive effects of celiprolol and enalapril.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Celiprolol; Clinical Trials as Topic; Enalapril; | 1988 |
[The effect of celiprolol on driving ability. An experimental psychological and comparative clinical study].
Topics: Adult; Automobile Driving; Celiprolol; Emotions; Humans; Hypertension; Male; Propanolamines; Psychom | 1985 |
[Comparative studies of the effect of a cardioselective and a noncardioselective beta-blocker on peripheral circulation in patients with arterial occlusive disease].
Topics: Aged; Arterial Occlusive Diseases; Blood Pressure; Celiprolol; Foot; Humans; Hypertension; Leg; Midd | 1986 |
[Plasma levels and the antihypertensive effect of the preparation celiprolol].
Topics: Acebutolol; Adult; Aged; Antihypertensive Agents; Celiprolol; Drug Evaluation; Female; Humans; Hyper | 1986 |
Celiprolol--review of airways studies.
Topics: Antihypertensive Agents; Asthma; Celiprolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind | 1988 |
Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Celiprolol; Clinical Trials as Topic; Double-Blind M | 1988 |
Systemic and renal hemodynamic effects of celiprolol in essential hypertensives.
Topics: Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Celiprolol; Clinical Trials as Topic; D | 1988 |
Comparison of the antihypertensive effects of celiprolol and acebutolol.
Topics: Acebutolol; Adult; Aged; Antihypertensive Agents; Blood Pressure; Celiprolol; Clinical Trials as Top | 1988 |
Effects of celiprolol on plasma renin, aldosterone, norepinephrine and epinephrine in primary hypertension.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Celiprolol; Double-Blind Method; Epinephrine; Fem | 1988 |
[Modification of the autonomic vascular reaction and peripheral circulation in the handgrip and orthostasis test by beta-blockage in patients with and without peripheral arterial occlusive disease].
Topics: Adult; Aged; Arousal; Arterial Occlusive Diseases; Blood Pressure; Celiprolol; Clinical Trials as To | 1988 |
Effect of long-term treatment with celiprolol on pulmonary function in a group of mild hypertensive asthmatics.
Topics: Adult; Aged; Antihypertensive Agents; Asthma; Celiprolol; Chlorthalidone; Clinical Trials as Topic; | 1988 |
Bronchoneutral effects in hypertensive asthmatics--celiprolol versus chlorthalidone.
Topics: Antihypertensive Agents; Asthma; Celiprolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind | 1988 |
24-h ambulatory non-invasive blood pressure monitoring in the assessment of the antihypertensive action of celiprolol.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Celiprolol; Diastole; Heart Rate; Humans; Hypertensi | 1988 |
44 other studies available for celiprolol and Hypertension
| Article | Year |
|---|---|
The effects of celiprolol on serum concentrations of proinflammatory cytokines in hypertensive (SHR) and normotensive (WKY) rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Celiprolol | 2014 |
Effects of the antioxidative beta-blocker celiprolol on endothelial progenitor cells in hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Celiprolol; Cell Movement; Cells, Cultured; Endo | 2008 |
Celiprolol inhibits mitogen-activated protein kinase and endothelin-1 and transforming growth factor-beta(1) gene in rats.
Topics: Adrenergic beta-Antagonists; Animals; Blotting, Western; Body Weight; Celiprolol; Desoxycorticostero | 2002 |
[Use of selective long-acting beta-blocker with vasodilating activity celiprolol in patients with essential hypertension].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Celipro | 2002 |
[Efficacy of beta-selective blocker with vasodilatating features celiprolol in patients with mild and moderate hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Celiprolol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; | 2003 |
Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 Via NF-kappaB induced by oxidative stress.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Celiprolol; Coronary Vessels; Desoxyc | 2003 |
The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Biomarkers; Blood Pressure; Carba | 2004 |
Concurrent dolichoectasia of basilar and coronary arteries.
Topics: Age of Onset; Aged; Aged, 80 and over; Antihypertensive Agents; Basilar Artery; Celiprolol; Coronary | 2006 |
[New drugs registered in Austria. Selectol].
Topics: Adrenergic beta-Antagonists; Animals; Austria; Celiprolol; Coronary Disease; Dogs; Drug Interactions | 1984 |
Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Celiprolol | 1993 |
[Celiprolol increases the microcirculation in subcutaneous tissue and calf muscles in essential hypertension].
Topics: Adult; Celiprolol; Extremities; Female; Humans; Hypertension; Leg; Male; Microcirculation; Middle Ag | 1993 |
Studies on placental transfer of celiprolol.
Topics: Celiprolol; Female; Humans; Hypertension; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complication | 1993 |
The role of renal dopamine in the reduction of high blood pressure by beta 1-selective beta-blocker with intrinsic sympathomimetic activity in spontaneously hypertensive rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressu | 1995 |
Effect of celiprolol therapy on arterial dilatation in experimental hypertension.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Animals; Celiprolol; Cyclic AMP; Hypertension; In Vitro | 1996 |
[Celiprolol improves glucose metabolism in essential hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Glucose; C-Peptide; Celiprolol; F | 1998 |
Effect of the beta 1-blocker/beta 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressu | 1998 |
Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney.
Topics: Adrenergic beta-Antagonists; Animals; Aorta, Thoracic; Benzopyrans; Celiprolol; Desoxycorticosterone | 1999 |
A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Cardiovascular Diseases; Celiprolol; Female; Hum | 1997 |
The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Biological Transport, Active; Blood G | 1999 |
[Safety and efficacy of celiprolol in hypertensive patients with chronic obstructive lung disease].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Ce | 2000 |
Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodeling in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Blotting, Western; Celiprolol; Collagen; Desox | 2001 |
Short-term effects of celiprolol on blood pressure and left ventricular performance in hypertensive cardiomyopathy.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiomegaly; Celiprolol; Echocardiography, Doppler; Fe | 1992 |
Celiprolol.
Topics: Antihypertensive Agents; Asthma; Celiprolol; Contraindications; Humans; Hypertension; Propanolamines | 1992 |
Celiprolol.
Topics: Antihypertensive Agents; Asthma; Celiprolol; Contraindications; Humans; Hypertension; Propanolamines | 1992 |
Cardiovascular mass and ventricular function after celiprolol in Wistar-Kyoto and spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Aorta; Celiprolol; Heart; Hypertension; Male; Organ Size; Prop | 1992 |
Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Cardiomegaly; Celiprolol; Echocardiography; Femal | 1992 |
Efficacy of celiprolol in the elderly hypertensive patient.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Cause of Death; Celiprolol; Glucose; Humans; Hype | 1991 |
[Celiprolol efficacy and tolerance in the treatment of arterial hypertension].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Celiprolol; Drug Evaluation; Drug Tolerance; F | 1991 |
[Acute changes of coronary and global hemodynamics in patients with angina pectoris and arterial hypertension caused by celiprolol and metoprolol].
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Celiprolol; Hemodynamics; Humans; Hypertension; | 1990 |
Clinical cardiac electrophysiologic study of celiprolol.
Topics: Adult; Aged; Bundle of His; Celiprolol; Coronary Disease; Electrocardiography; Electrophysiology; Fe | 1986 |
Mechanism of smooth muscle contraction: relevance to safety of beta-adrenergic blockade in hypertensive patients with reversible chronic obstructive airways disease.
Topics: Adrenergic beta-Antagonists; Atenolol; Bronchi; Calcium Channel Blockers; Calmodulin; Celiprolol; Cy | 1986 |
Celiprolol, clinical dosage, efficacy and safety in asthmatic and elderly patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Asthma; Celiprolol; Drug Evaluation; Humans; Hypertension; | 1985 |
A comparative study of celiprolol and chlorthalidone in hypertensive patients with reversible airways obstruction.
Topics: Adrenergic beta-Antagonists; Asthma; Celiprolol; Chlorthalidone; Drug Evaluation; Humans; Hypertensi | 1985 |
A comparison of celiprolol and atenolol in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Atenolol; Celiprolol; Drug Evaluation; Humans; Hypertension; Propanolam | 1985 |
A comparison of celiprolol and propranolol in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Celiprolol; Drug Evaluation; Humans; Hypertension; Propanolamines; Prop | 1985 |
A symposium: Hypertension into the nineties. September 6, 1986, Heidelberg, FRG.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Celiprolol; Humans; Hypertension; Propanolamin | 1988 |
Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprolol.
Topics: Adrenergic beta-Antagonists; Airway Resistance; Antihypertensive Agents; Atenolol; Celiprolol; Diabe | 1988 |
Celiprolol--new clinical perspectives beyond cardioselectivity. Proceedings of a symposium. Madrid, Spain, 24 January 1987.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Celiprolol; Humans; Hypertension; Propanolamin | 1988 |
Lipid profile improvement following celiprolol.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Body Weight; Celiprolol; Cholesterol; Cholestero | 1988 |
[Results of the selectol field study in Austria].
Topics: Adolescent; Adult; Aged; Celiprolol; Female; Humans; Hypertension; Male; Middle Aged; Product Survei | 1985 |
Effects of celiprolol on serum lipids in systemic hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Celiprolol; Heart Rate; Humans; Hypertension; Lipids | 1988 |
Reduction of left ventricular hypertrophy in hypertensive patients after treatment with celiprolol.
Topics: Adult; Antihypertensive Agents; Cardiomegaly; Celiprolol; Echocardiography; Female; Humans; Hyperten | 1988 |
[Hemodynamic effect of a combination of prazosin with cardiac depressants in the treatment of hypertension].
Topics: Anti-Arrhythmia Agents; Celiprolol; Clonidine; Drug Evaluation; Drug Synergism; Drug Therapy, Combin | 1988 |
Long-term humoral and hemodynamic effects of celiprolol.
Topics: Adult; Blood Pressure; Celiprolol; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Pr | 1988 |